Össur hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and … Read more
Össur hf (OSSUY) - Net Assets
Latest net assets as of December 2025: $895.96 Million USD
Based on the latest financial reports, Össur hf (OSSUY) has net assets worth $895.96 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.75 Billion) and total liabilities ($850.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $895.96 Million |
| % of Total Assets | 51.3% |
| Annual Growth Rate | 5.95% |
| 5-Year Change | 42.99% |
| 10-Year Change | 90.38% |
| Growth Volatility | 5.08 |
Össur hf - Net Assets Trend (2013–2025)
This chart illustrates how Össur hf's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Össur hf (2013–2025)
The table below shows the annual net assets of Össur hf from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $895.96 Million | +14.76% |
| 2024-12-31 | $780.70 Million | +10.74% |
| 2023-12-31 | $705.01 Million | +10.94% |
| 2022-12-31 | $635.51 Million | +1.42% |
| 2021-12-31 | $626.60 Million | +8.56% |
| 2020-12-31 | $577.19 Million | +1.45% |
| 2019-12-31 | $568.96 Million | +5.84% |
| 2018-12-31 | $537.54 Million | +7.41% |
| 2017-12-31 | $500.46 Million | +6.34% |
| 2016-12-31 | $470.60 Million | +1.64% |
| 2015-12-31 | $463.02 Million | +8.27% |
| 2014-12-31 | $427.65 Million | -4.55% |
| 2013-12-31 | $448.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Össur hf's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 245.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $842.72 Million | 94.61% |
| Common Stock | $4.84 Million | 0.54% |
| Other Comprehensive Income | $-50.50 Million | -5.67% |
| Other Components | $93.65 Million | 10.51% |
| Total Equity | $890.70 Million | 100.00% |
Össur hf Competitors by Market Cap
The table below lists competitors of Össur hf ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Ankura Smart Transmission Engineering Technology Co Ltd
SHE:300617
|
$660.37 Million |
|
Changjiang Publishing & Media Co Ltd
SHG:600757
|
$660.57 Million |
|
Republic Bancorp Inc
NASDAQ:RBCAA
|
$660.80 Million |
|
Television Francaise 1 SA
PA:TFI
|
$660.99 Million |
|
Nh Special Purpose Acquisition 14 Co. Ltd
KQ:319400
|
$660.01 Million |
|
Alstom PK
PINK:ALSMY
|
$659.84 Million |
|
URW (STAPL.SHS CDI)EO-05
F:UBLB
|
$659.78 Million |
|
Jiangsu SINOJIT Wind Energy Technology Co Ltd
SHG:601218
|
$659.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Össur hf's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 777,186,000 to 890,703,332, a change of 113,517,332 (14.6%).
- Net income of 83,654,567 contributed positively to equity growth.
- Share repurchases of 9,790,282 reduced equity.
- Other comprehensive income increased equity by 24,888,250.
- Other factors increased equity by 14,764,797.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $83.65 Million | +9.39% |
| Share Repurchases | $9.79 Million | -1.1% |
| Other Comprehensive Income | $24.89 Million | +2.79% |
| Other Changes | $14.76 Million | +1.66% |
| Total Change | $- | 14.61% |
Book Value vs Market Value Analysis
This analysis compares Össur hf's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.11x to 1.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.99 | $4.08 | x |
| 2014-12-31 | $0.94 | $4.08 | x |
| 2015-12-31 | $1.04 | $4.08 | x |
| 2016-12-31 | $1.07 | $4.08 | x |
| 2017-12-31 | $1.16 | $4.08 | x |
| 2018-12-31 | $1.25 | $4.08 | x |
| 2019-12-31 | $1.33 | $4.08 | x |
| 2020-12-31 | $1.35 | $4.08 | x |
| 2021-12-31 | $1.47 | $4.08 | x |
| 2022-12-31 | $1.52 | $4.08 | x |
| 2023-12-31 | $1.67 | $4.08 | x |
| 2024-12-31 | $1.82 | $4.08 | x |
| 2025-12-31 | $2.09 | $4.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Össur hf utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.39%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.97%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.96x
- Recent ROE (9.39%) is below the historical average (9.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 9.01% | 9.28% | 0.61x | 1.58x | $-4.41 Million |
| 2014 | 13.85% | 11.67% | 0.76x | 1.56x | $16.43 Million |
| 2015 | 11.09% | 10.61% | 0.73x | 1.43x | $5.02 Million |
| 2016 | 10.84% | 9.80% | 0.69x | 1.60x | $3.93 Million |
| 2017 | 11.51% | 10.14% | 0.71x | 1.59x | $7.57 Million |
| 2018 | 14.92% | 13.01% | 0.67x | 1.71x | $26.31 Million |
| 2019 | 11.70% | 9.62% | 0.63x | 1.93x | $9.60 Million |
| 2020 | 1.09% | 0.99% | 0.52x | 2.13x | $-51.04 Million |
| 2021 | 10.30% | 8.90% | 0.58x | 2.01x | $1.84 Million |
| 2022 | 6.69% | 5.92% | 0.54x | 2.09x | $-21.06 Million |
| 2023 | 8.32% | 7.43% | 0.56x | 1.99x | $-11.80 Million |
| 2024 | 8.79% | 7.99% | 0.55x | 2.00x | $-9.44 Million |
| 2025 | 9.39% | 8.97% | 0.53x | 1.96x | $-5.42 Million |
Industry Comparison
This section compares Össur hf's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Össur hf (OSSUY) | $895.96 Million | 9.01% | 0.95x | $660.31 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |